This 28% Short Biotech Company Has A Better 1-Year Return Than AMC, Snap, Apple And Tesla
An investment in Ocugen Inc (NASDAQ: OCGN) one year ago is undoubtedly a sight for sore eyes.
‘Health Ministry in response to an RTI query, says it has made an advance payment to SII for covishield at ₹215/dose & Bharat Biotech for covaxin at ₹226/dose, no order for sputnik yet.’ – CNBC-TV18
https://twitter.com/CNBCTV18News/status/1433740287189270535
‘Bharat Biotech’s intranasal vaccine trials begin in Kanpur, UP’ – HinduPost
https://hindupost.in/health/bharat-biotechs-intranasal-vaccine-trials-begin-in-kanpur-up/
Analyzing Ocugen’s Unusual Options Activity
Ocugen (NASDAQ:OCGN) shares experienced unusual options activity on Thursday. The stock price moved down to $6.92 following the option alert.
UK Updates Summary Of Product Characteristics, Product Information For Moderna’s COVID-19 Vaccine To Say Product Authorized In Individuals Aged 12+ Years
https://www.gov.uk/government/news/moderna-covid-19-vaccine-approved-by-mhra-in-12-17-year-olds
Do mRNA COVID-19 Vaccines Cause Skin Or Kidney Disorders? EMA Investigates Possible Links
The European Medicines Agency is investing a possible link between mRNA vaccines and erythema multiforme or two kidney disorders by…